Screening for prostate cancer by using random-effects models

被引:21
作者
Brant, LJ
Sheng, SL
Morrell, CH
Verbeke, GN
Lesaffre, E
Carter, HB
机构
[1] NIA, Gerontol Res Ctr, Baltimore, MD 21224 USA
[2] Loyola Coll, Baltimore, MD 21210 USA
[3] Katholieke Univ Leuven, Louvain, Belgium
[4] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
关键词
cancer diagnosis; classification; disease screening; linear mixed effects model; longitudinal-data; prostate-specific antigen;
D O I
10.1111/1467-985X.00258
中图分类号
O1 [数学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 0701 ; 070101 ;
摘要
Random-effects models are used to screen male participants in a long-term longitudinal study for prostate cancer. By using posterior probabilities, each male can be classified into one of four diagnostic states for prostate disease: normal, benign prostatic hyperplasia, local cancer and metastatic cancer. Repeated measurements of prostate-specific antigen, collected when there was no clinical evidence of prostate disease, are used in the classification process. An individual's screening data are considered one repeated measurement at a time as his data are collected longitudinally over time. Posterior probabilities are calculated on the basis of data from other individuals with confirmed diagnoses of each of the four diagnostic states.
引用
收藏
页码:51 / 62
页数:12
相关论文
共 28 条
  • [1] PRACTICAL PROBLEMS IN FITTING A PROPORTIONAL HAZARDS MODEL TO DATA WITH UPDATED MEASUREMENTS OF THE COVARIATES
    ALTMAN, DG
    DESTAVOLA, BL
    [J]. STATISTICS IN MEDICINE, 1994, 13 (04) : 301 - 341
  • [2] Bycott P, 1998, STAT MED, V17, P2061, DOI 10.1002/(SICI)1097-0258(19980930)17:18<2061::AID-SIM896>3.3.CO
  • [3] 2-F
  • [4] CARTER HB, 1994, SEMIN ONCOL, V21, P554
  • [5] CARTER HB, 1990, PROSTATE, V16, P39
  • [6] LONGITUDINAL EVALUATION OF PROSTATE-SPECIFIC ANTIGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE DISEASE
    CARTER, HB
    PEARSON, JD
    METTER, J
    BRANT, LJ
    CHAN, DW
    ANDRES, R
    FOZARD, JL
    WALSH, PC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (16): : 2215 - 2220
  • [7] MEASUREMENT OF PROSTATE-SPECIFIC ANTIGEN IN SERUM AS A SCREENING-TEST FOR PROSTATE-CANCER
    CATALONA, WJ
    SMITH, DS
    RATLIFF, TL
    DODDS, KM
    COPLEN, DE
    YUAN, JJJ
    PETROS, JA
    ANDRIOLE, GL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) : 1156 - 1161
  • [8] PROSTATE-CANCER DETECTION IN A CLINICAL UROLOGICAL PRACTICE BY ULTRASONOGRAPHY, DIGITAL RECTAL EXAMINATION AND PROSTATE SPECIFIC ANTIGEN
    COONER, WH
    MOSLEY, BR
    RUTHERFORD, CL
    BEARD, JH
    POND, HS
    TERRY, WJ
    IGEL, TC
    KIDD, DD
    [J]. JOURNAL OF UROLOGY, 1990, 143 (06) : 1146 - 1154
  • [9] Evaluating surrogate markers of clinical outcome when measured with error
    Dafni, UG
    Tsiatis, AA
    [J]. BIOMETRICS, 1998, 54 (04) : 1445 - 1462
  • [10] De Stavola B L, 1996, Lifetime Data Anal, V2, P329